LNTH
Lantheus Holdings, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$101.09
+0.29%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$100.88
From 52W high−8.88%
Volume769321.00
Market cap$6.60B
P/E (TTM)24.0x
P/S (TTM)4.2x
Div yield—
Key dataNov 4, 2026
Open
$100.88
From 52W high
−8.88%
Volume
769321.00
Market cap
$6.60B
ValuationView details →
P/E (Fwd)
16.8x
EV/EBITDA
14.1x
P/E (TTM)
24.0x
RSI (14)
64.5
MomentumView details →
1D Return
+0.29%
YTD Return
+51.90%
SummaryUpdated Jun 1, 2026
Lantheus Holdings, Inc. (NASDAQ:LNTH) is a specialized pharmaceutical company founded in 1956 and headquartered in North Billerica, Massachusetts. The company develops, manufactures, and commercializes diagnostic and therapeutic radiopharmaceuticals that assist clinicians in diagnosing and treating heart disease, cancer, and other conditions. Originally focused on traditional nuclear medicine products, Lantheus has transformed into a leading player in the rapidly growing radiopharmaceutical oncology market, particularly through its blockbuster PSMA PET imaging agent PYLARIFY, which became the first radiopharmaceutical to exceed $1 billion in annual sales.
Similar companies
Latest newsMore news →
Multiple banks are competing to join a $4.25 billion debt financing for Curium US Holdings LLC’s acquisition of Lantheus Holdings, Inc., ahead of a planned syndication to investors next year.20d agoThe Centers for Medicare & Medicaid Services granted transitional pass-through status to Lantheus' PYLARIFY TruVu (piflufolastat F 18) PSMA PET imaging agent, alongside a permanent HCPCS code effective October 1, 2026.35d agoLantheus withdrew and resubmitted its Hart-Scott-Rodino filing for its acquisition of Curium.44d ago